Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder

European Urology

Volumn 43, Issue 2, 2003, Pages 138-145

  Krüger, Stefan ^a   Thorns, Christoph ^a   Stöcker, Winfried ^b   Müller Kunert, Ewald ^b   Böhle, Andreas ^a   Feller, Alfred C ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Institute of Experimental Immunology   (Germany)

Author keywords

Bladder cancer; Immunoreactivity; MCM2; Prognosis; Proliferation

Indexed keywords

KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DNA MICROARRAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; TRANSITIONAL CELL CARCINOMA;

EID: 0037323421     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00580-8     Document Type: Article

References (43)

1. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 2000;88:2598-605.
2. deVere-White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, et al. The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. Eur Urol 2000;37:595-600.
3. Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N, et al. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 2001;92:510-8.
4. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 1997;80:1472-81.
5. Gontero P, Casetta G, Zitella A, Ballario R, Paccioni D, Magnani C, et al. Evaluation of p53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 2000;38:287-96.
6. Wu TT, Chen JH, Lee YH, Huang JK. The role of bcl-2, p53, and Ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 2000;163:758-60.
7. Kuczyk MA, Serth J, Bokemeyer C, Hervatin C, Oelke M, Oelert F, et al. Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder. Urologe A 1995;34:146-52.
8. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996;78:1762-74.
9. Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI. Decreasing of p27 (Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001;84:1242-51.
10. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with waf1, pRb and Ki67. Br J Cancer 2001;84:270-5.
11. Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, et al. Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 2002;97:671-8.
12. Leissner J, Hohenfellner R, Thüroff JW, Köppen C, Wolf HK. Prognostic significance of histopathological grading and immunoreactivity for p53 and p21/WAF1 in grade 2 pTa transitional cell carcinoma of the urinary bladder. Eur Urol 2001;39:438-45.
13. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-32.
14. Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, et al. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 2001;7:2712-8.
15. Ramnath N, Hernandez FJ, Tan DF, Huberman JA, Natarajan N, Beck AF, et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol 2001;19:4259-66.
16. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH. Replicative MCM2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neuobiol 2001;27:305-13.
17. Stoeber K, Halsall I, Freeman A, Swinn R, Doble A, Morris L, et al. Immunoassay for urothelial cancers that detects DNA replication protein Mcm5 in urine. Lancet 1999;354:1524-5.
18. Sauter G, Mihatsch MJ. Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same! J Pathol 1998;185:339-41.
19. Mostofi F, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. In: International Histological Classification of Tumours, No 10. Geneva: WHO; 1973. p. 16-7.
20. Stöcker W, Teegen B, Meyer W, Müller-Kunert E, Proost S, Schlumberger W, Sonnenberg K. Differenzierte Autoantikörper-Diagnostik mit BIOCHIP-Mosaiken. In: Conrad K, editor. Autoantikörper. Lengerich: Pabst; 1998. p. 78-99.
21. Stöcker W. Moderne Techniken für die Histochemie. Verh Anat Ges 1987;81:473-4.
22. Kuczyk MA, Serth J, Hervatin C, Arndt H, Derendorf L, Thon WF, et al. Detection of p53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications. World J Urol 1994;12:345-51.
23. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga MLTH, Seymour GJ. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 1994;73:526-32.
24. Friedrich MG, Blind C, Milde-Langosch K, Erbersdobler A, Conrad S, Löning T, et al. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol 2001;40:518-24.
25. Wolf HK, Stöber C, Hohenfellner R, Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumor Biol 2001;22:328-36.
26. Hermann GG, Horn T, Steven K. The influence of the level of lamina propria invasion and the prevalence of p53 nuclear accumulation on survival in stage T1 transitional cell bladder cancer. J Urol 1998;159:91-4.
27. Llopis J, Alcaraz A, Ribal MJ, Sole M, Ventura PJ, Barranco MA, et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000;37:644-53.
28. Ritzi M, Knippers R. Initiation of genome replication: assembly and disassembly of replication-competent chromatin. Gene 2000;245:13-20.
29. Stoeber K, Mills AD, Kubota Y, Krude T, Romanowski P, Marheineke K, et al. Cdc6 protein causes premature entry into S phase in a mammalian cell-free system. EMBO J 1998;17:7219-29.
30. Williams GH, Romanowski P, Morris L, Madine M, Mills AD, Stoeber K, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA 1998;95:14932-7.
31. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
32. MacCallum DE, Hall PE. The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle. J Pathol 2000;190:537-44.
33. Verheijen R, Kuijpers HJ, van Driel R, Beck JL, van Dierendonck JH, Brakenhoff GJ, et al. Ki67 detects a nuclear matrix-associated proliferation related antigen. II. Localisation in mitotic cells and association with chromosomes. J Cell Sci 1989;92:531-40.
34. Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bohrow L, et al. DNA replication licensing and human cell proliferation. J Cell Sci 2001;114:2027-41.
35. Masters JR, Camplejohn RS, Parkinson MC, Woodhouse CR. DNA ploidy and the prognosis of stage pT1 bladder cancer. Br J Urol 1989;64:403-8.
36. Kaubisch S, Lum BL, Reese J, Freiha F, Torti FM. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991;146:28-31.
37. Llopis J. Alcaraz A, Ribal MJ, Sole M, Venura PJ, Barranco MA, et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur Urol 2000;37:644-53.
38. Cookson MS, Sarosdy MF. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J Urol 1992;148:797-801.
39. Dinney CP, Babkowski RC, Antelo M, Perrotte P, Liebert M, Zhang HZ, et al. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. J Urol 1998;160:1285-90.
40. Richter J, Wagner U, Schraml P, Maurer R, Alund G, Knönagel H, et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res 1999;59:5687-91.
41. Jakse G, Loidl W, Seeber G, Hofstädter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavourable tumor? J Urol 1987;137:39-43.
42. Richter J, Jiang F, Görög JP, Sartorius G, Egenter C, Gasser TC, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997;57:2860-4.
43. Nocito A, Bubendorf L, Maria-Tinner E, Suess K, Wagner U, Forster T, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-57.